PATENT CLAIM ANALYSIS

Application Number: 15901439
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-12
Patent Classification: ["514", "397000"]

Abstract:
The present disclosure comprises a method for administering 2,3-dihydro-isoindole-1-one compound or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, for the treatment of hematological cancers such as acute myeloid leukemia (AML). The present disclosure further relates to reducing or inhibiting cell-proliferation which is activated by wild-type or mutated Fms-like tyrosine kinase-3 receptor (FLT3). The present disclosure further relates to a method of inhibiting or reducing abnormal (e.g., overexpressed) wild-type or mutated BTK activity or expression in a subject in need thereof.

Claim (Index 176):
The method of  claim 173 , wherein the at least one point mutation is two or more point mutations present on the same allele.

Metadata:
- Claim Count in Document: 87.0
- Percentile: 88.0
- Lexical Diversity: 1.58333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15581736', '14053011', '15101240', '14820434', '14671613']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7924226126200336
- 35 USC 102 Novelty (BERT): 0.5363586477022306
- Combined Prediction Score: 0.7668162161282533
- Mean Citation Score: 348.025778
- Max Citation Score: 372.31412
- Similarity Product: 218.93929898589369

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test